Background: Radioactive iodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC). Nevertheless, the mechanism of RAI resistance that occurs in many patients with DTC remains unknown. We aimed to elucidate the role of post-translational regulation of radioiodine uptake. Methods: We analyzed the expression pattern of the ribosomal glycosylphosphatidylinositol transamidase (GPIT) complex in freshly excised tumors from 10 patients with DTC. We used functional RAI uptake assays to assess the role of GPIT in iodine uptake both in vivo and in vitro. The effects of MEK inhibition on the GPIT subunit PIGU and the sodium iodide symporter (NIS) were assessed in three DTC cell lines and in four human DTC biopsies. We used a multivariable logistic regression model to study the role of PIGU in the response to RAI treatment in advanced DTC. All statistical tests were two-sided. Results: Expression profiling of different GPIT complex subunits revealed statistically significantly lower expression of PIGU in papillary carcinomas than in matched normal thyroid tissue (P < .001). Expression of PIGU in the K1 human papillary carcinoma cell line resulted in a robust increase in NIS glycosylation and trafficking to the cell membrane, accompanied by a robust increase in I 125 uptake both in vitro (465 200 6 56 343 vs 1236 6 156 counts per million, P < .001) and in vivo (128 945 6
Tumor ability to trap iodine is mainly controlled by the sodium iodide symporter (NIS), which is downregulated in thyroid cancer (4, 5) . One option for the low expression of membranous NIS is defective post-translational modification (6) (7) (8) (9) (10) (11) (12) (13) . At the endoplasmic reticulum (ER), the crucial steps of cleaving the signal sequence and attaching the preassembled glycosylphosphatidylinositol (GPI) anchor are catalyzed by GPI transamidase (GPIT), a multisubunit membrane-bound enzyme. The mammalian GPIT complex consists of five proteins, namely PIGK, GPAA1, PIGS, PIGT, and PIGU. Previously, alterations in expression of the GPIT complex subunit were shown to induce malignant transformation in vitro and in vivo (14) . Hence, components of the GPIT complex may function either independently or as a group to promote tumorigenesis (14) (15) (16) (17) .
In the current study, we hypothesized that PIGU downregulation in thyroid carcinoma inhibits NIS glycosylation and trafficking to the cell membrane, which results in reduced radioiodine uptake. We aimed to evaluate whether mitogen-activated protein kinase (MEK) targeting can modulate PIGU expression. Finally, we explored PIGU expression as predictor to radioactive iodine (RAI) response both in vivo and in a patient cohort.
Methods

Patients
Experiments were approved by the Rambam Health Care Campus Institutional Review Board protocols 0238-13-RMB and 0469-12-RMB. Written informed consent was obtained from all participants.
For analysis of NIS and PIGU protein expression (by immunohistochemistry) and mRNA levels (by quantitative polymerase chain reaction [qPCR]), we used fresh tissue specimens obtained from 10 patients who underwent total thyroidectomy for primary unilateral PTC (stage T1/2). The contralateral lobe (without tumor) was used as normal control.
For RAI uptake and thyroglobulin levels after RAI treatment, we analyzed 18 patients who were treated for differentiated thyroid carcinoma of follicular cell origin, histopathologically confirmed at the Rambam Health Care Campus, between 2010 and 2015. Each of these patients underwent total thyroidectomy with or without neck dissection for their primary tumor, followed by RAI treatment. They were treated a second time with RAI at disease recurrence. Study inclusion criteria included 1) recurrent disease treated with RAI alone, 2) available diagnostic radioiodine scanning performed up to six months before the recurrence, 3) available thyroglobulin and antithyroglobulin Ab data prior to treatment and during follow-up, and 4) available tissue for immunohistochemical analysis of NIS and PIGU. Undetectable thyroglobulin values clinically reported as less than 0.2 ng per milliliter were assigned a value of 0.2 ng per milliliter for calculations.
Mouse Models of Tumor Growth, Invasion, and Vocal Fold Function
All experimental procedures were performed in accordance with the Institutional Animal Care and Use Committee and the Department of Agriculture regulations. Orthotopic tumors were induced by direct injection of 5Â10 5 isogenic differentiated thyroid carcinoma cells in 20 uL into the right thyroid lobe of fourto six-week-old female athymic nu/nu mice (Harlan, Jerusalem, Israel, n ¼ 10 per group). Tumors were scanned biweekly with a Vevo 2100 small animal micro-imaging system (VisualSonics, Toronto, Ontario, Canada) to assess growth, local invasion, and vocal fold function.
In vivo I 125 Uptake and Scintigraphy
When a 5 to 10 mm tumor was present at the flank, mice were subjected to thyroidectomy, Recombinant thyroid stimulating hormone (rTSH) treatment, I 125 administration, and imaging prior to death, as described below (n ¼ 5 mice per group).
Imaging was performed on a clinical Single-photon emission computed tomography (SPECT)/CT camera (GE Discovery 670), with the energy window set at 35.5 keV 6 15%. Planar images were acquired for 15 minutes, and SPECT/CT images were acquired for 30 minutes (120 projections, 15 s/position, matrix size 128Â128). Immediately after imaging, tumors were harvested, weighed, and their I 125 activity was counted using a c-counter.
Emissions are presented in mean counts per million/gr6SD.
The Cancer Genome Atlas Analysis
The Cancer Genome Atlas (TCGA) (18, 19) sequencing data is publicly available at the cBioPortal for Cancer Genomics (http:// www.cbioportal.org/). Mutation plots were generated using the OncoPrinter (v. 1.0.1) and MutationMapper (v. 1.0.1) tools, which are available at the cBioPortal.
Statistics
The primary end point was the ratio of radioactive iodine-avid tumors, as quantified by I 131 scan at recurrence. A two-tailed chi-square test with a type 1 error of 5% was used to compare I 131 uptake rates of PIGU-positive and PIGU-negative tissues.
A secondary end point was serum thyroglobulin levels after treatment with I 131 for non-surgically treated recurrences.
Patients were observed for nine to 12 months after RAI treatment, and paired before-RAI and after-RAI serum thyroglobulin levels were compared by a Wilcoxon signed-rank test. A multivariable analysis (Supplementary Methods, available online) using logistic regression of response (defined as less than 30% of the pretreatment thyroglobulin levels) was performed to assess variables that had possible prognostic potential, as suggested by the univariate analysis (20) . All statistics were two-sided. A P value of less than .05 was considered statistically significant. Methods for the in vitro radioiodine uptake assay, clonogenic survival assay, cell culture, immunohistochemistry, proliferation assay, immunoblotting, flow cytometry, and real-time PCR are described in the Supplementary Methods (available online).
Results
Regulation of PIGU in Papillary Thyroid Cancer
Previous data suggested that the GPIT complex might be involved in post-translational regulation during oncogenesis. Analysis of 516 PTC samples included in The Cancer Genome Atlas revealed mRNA upregulation in any one of the GPIT complex subunits (PIGU, PIGT, GPAA1, PIGS, and PIGK) in 70 (13.5%) of the patients and mRNA downregulation in 24 (4.6%) of the patients (data not shown, available at the cBioPortal for Cancer Genomics; http://www.cbioportal.org/) (18, 19) . To further explore the involvement of the GPIT complex in PTC oncogenesis, we compared expression patterns of its subunits in the PTC cell ARTICLE line (K1) and in PTC specimens freshly excised from 10 patients with unilateral T1-2 classification PTC (for clinical and pathological features of these patients, see Supplementary Table 1, available online). We used follicular cells from the tumor-free lobe as controls. Our analysis revealed a statistically significant reduction, by 72.3% (P ¼ .01, Welch's t test), in the PIGU mRNA expression level in PTC compared with normal cells ( Figure 1A) . Analysis of the TCGA data revealed that 95.4% of the tumors had no alterations in PIGU mRNA levels, and it revealed no correlation between PIGU status and BRAF/NRAS/HRAS mutation status or histologic variant (ie, follicular or tall cell variant). The TCGA mRNA expression computes the relative expression of an individual gene and tumor to the gene's expression distribution in a reference population; that reference population includes all tumors that are diploid for the gene in question and not normal thyroid tissue. Hence, comparison of PIGU expression in this population should be focused on comparison between normal and cancerous tissues.
We used samples from the same cohort to further explore the degree of PIGU expression using immunolabeling (n ¼ 10).
While normal follicular cells had abundant perinuclear expression of PIGU, thyroid cancer cells showed sparse cytoplasmic expression of PIGU (mean numbers of PIGU-expressing cells ¼ 3366 and 261/HPF, respectively; n ¼ 10, P ¼ .02, Welch's t test) ( Figure 1B) .
To further characterize the role of GPI anchoring on PTC progression, we generated an isogenic DTC K1 cell line overexpressing PIGU (K1-PIGU) by stable transfection ( Figure 1C ). As shown in Figure 1D , there was no statistically significant difference in the proliferation of K1-PIGU compared with mock-transfected cells. We also did not find a statistically significant difference in migration (P ¼ .53) ( Figure 1E ) or cell motility (275635 vs 310641 mm after 24 hours, P ¼ .82, Welch's t test) ( Figure 1F ) between K1 control and K1-PIGU cells, respectively.
To further determine whether PIGU influences tumor growth, we induced orthotopic tumors using K1 control and K1-PIGU cells injected into the thyroids of nu/nu mice (n ¼ 10 per group). Mice were followed biweekly by ultrasound scans for four weeks; tumor growth and vascularity were examined as staining of human PTC and contralateral thyroid lobe normal thyroid using anti-PIGU Ab. Scale bar ¼ 50 lm. C) Immunoblotting for PIGU of a PIGU stably transfected K1-PTC cell lines (K1-PIGU). We used three distinct clones for transfection. D) Proliferation, (E) migration, and (F) motility rates of K1 and K1-PIGU cells. G) In vivo growth curves as measured by ultrasound scans of orthotopic K1 and K1-PIGU tumors (n ¼ 10 mice per group). Error bars represent 95% confidence intervals. P values were calculated using the two-sided Welch's t test; all experiments were repeated at least three times. PTC ¼ papillary thyroid carcinoma.
ARTICLE
previously described. To ascertain stable transfection, a tissue sample of the excised tumor was lysed and blotted for PIGU (data not shown). There was no difference in tumor size between the groups (2266 vs 2666 mm 3 for K1 control and K1-PIGU respectively, P ¼ .74, Welch's t test) ( Figure 1G ). We also found no difference in tumor vascularity using power Doppler imaging; the calculated percent area of vascularization (PV) was 22.3% for K1-PIGU cells compared with 28.1% for K1 cells (P ¼ .33, Welch's t test).
Post-translational Modification of Sodium-Iodide Symporter by PIGU
We assessed NIS mRNA transcription in the TCGA PTC database (n ¼ 516). Analysis of the expression levels of NIS mRNA revealed NIS mRNA upregulation in six (1.6%) patients. Only one patient with altered NIS mRNA carried the BRAF mutation, and two patients had follicular variant PTC. We used the same matched PTC/normal thyroid cohort (n ¼ 10) (Supplementary Table 1 , available online) fresh samples to assess NIS expression. First, immunohistochemistry staining of the papillary carcinoma specimens (n ¼ 10) revealed low expression of NIS relative to normal thyroid tissue (mean numbers of NIS expressing cells ¼ 161 and 2664/HPF, respectively, P < .001, Welch's t test) ( Figure 2A ). To evaluate the regulatory effect of PIGU on NIS expression, we analyzed the mRNA levels of NIS in the freshly excised PTC and follicular cells (n ¼ 10). Quantitative real-time PCR analysis revealed no statistically significant difference in the level of NIS mRNA expression in PTC or normal thyroid cells (Supplementary Figure 1A , available online). Taken together, these findings indicate that NIS dysregulation occurs in the presence of unaltered NIS mRNA transcription. Cross-sectional confocal images revealed that most of the NIS molecules were located in the perinuclear compartment of K1 cells after treatment with mock plasmid. However, after forcing PIGU expression, the NIS proteins were redistributed in the cell membrane ( Figure 2B ). High-resolution serial confocal pictures of the subcellular localization of NIS are shown in Supplementary Figure 2 (available online). To address the role of the GPIT complex in NIS expression and subcellular localization, we assessed the cell surface expression levels of NIS and the canonical GPIT-dependent protein, decay-accelerating factor (DAF, also known as CD55), using flow cytometry. Overexpression of PIGU in K1-PIGU cells led to a marked increase in GPIT complex activity, as reflected by augmented DAF expression, in parallel to a rise in the surface expression of NIS ( Figure 2C ).
The observation that PIGU expression affects NIS trafficking to the membrane raises the question of whether NIS is a GPIanchored protein. Proteins that are substrates for GPI lipid anchoring have a four-partite sequence signal at their C-terminus in addition to other sequence signals (typically a signal leader peptide) that translocate the nascent protein into the endoplasmic reticulum (21) . We further evaluated the molecular structure of NIS using the "big-PI" predictor algorithm (22) (available at http://mendel.imp.ac.at/sat/gpi/gpi_server.html). In the case of the C-terminal sequence of NIS/SCL5A5 (Q92911, NP_000444.1), sequence-analytical evidence reliably excludes NIS/SCL5A5 as a possible substrate for GPI lipid anchoring (see the Supplementary Methods, available online). Manual inspection of the sequence confirmed this finding.
We next investigated whether PIGU influences the glycosylation of NIS. Immunoblotting analyses of the glycosylated (130 kDa) (8, 23, 24) and nonglycosylated (70$80 kDa) forms of NIS were assessed in K1 and K1-PIGU cells. Figure 2D shows that PIGU expression slightly increased the nonglycosylated forms of NIS (70 kDa) but induced a greater than twofold increase in the glycosylated form of NIS (130 kDa). Of note, treating K1-PIGU with glycosylation inhibitor (tunicamycin 1.2 mM) (24) resulted in a diminished glycosylated NIS expression.
To assess NIS protein stability, we performed immunoblot 48, 72, and 96 hours after treating K1 and K1-PIGU with cycloheximide (25) . This analysis showed that K1-PIGU cells had increased steady state (ie, at t ¼ 0 and 48 hours) levels of NIS compared with K1 cells. Furthermore, the protein levels after 96 hours were lower in the K1-PIGU cells compared with K1 cells (see Supplementary Figure 3 , available online). These findings suggest that post-translation modification of NIS (70 kDa) by PIGU influences NIS expression.
Impact of PIGU on Papillary Thyroid Carcinoma Cells Sensitivity to Radioactive Iodine
As overexpression of PIGU induces NIS expression on the cell surface, we examined the ability of PTC cells to concentrate RAI. Figure 2E shows that K1-PIGU cells had a statistically significant increase in RAI (I 125 ) uptake compared with K1 control cells (465 200 6 56 343 vs 1236 6 156 counts per million, P < .001). Similarly, in other thyroid carcinoma cell lines (ie, TPC1 and BCPAP), PIGU overexpression resulted in a statistically significant increase in RAI uptake in TPC1 and BCPAP while there was a modest increase in RAI uptake in the poorly differentiated 8505C thyroid carcinoma cell line (Supplementary Figure 1 , available online). Notably, PIGU overexpression did not yield a statistically significant change in the NIS mRNA levels in any of these cell lines. Interestingly, treating thyroid follicular cells Nthy-ori 3-1 with small interfering RNA (siRNA) directed against PIGU didn't result in a statistically significant reduction of NIS membranous expression (73.4% 6 33.1% and 81.3% 6 35.2% of the Nthy-ori 3-1 cells treated with siControl and siPIGU, respectively, had NIS membranous expression) or RAI uptake (Supplementary Figure 4 , available online).
Radioactive iodine can induce DNA double-strand breaks and genomic instability in PTC cells. We monitored the effect of RAI on K1-PIGU and K1 cells using phosphorylated histone H2AX (cH2AX) and 16 mCi/mL I
125
. Figure 2F shows a statistically significant increase in cH2AX expression in K1-PIGU cells but not in K1 control cells 72 hours after RAI treatment (11.42 6 4.36 and 1.166 1.01 cH2AX-positive foci per positive cell, P < .001, n > 50).
To explore whether these findings lead to growth arrest in thyroid cancer cells, we performed the clonogenic survival assays with escalating doses of RAI (0-64 mCi). Two hours after incubation, cells were washed and surviving colonies were allowed to form for 96 hours. 
PIGU Effect on Radioiodine Uptake In Vivo
We further assessed the role of PIGU in radioiodine uptake in vivo using K1 control and K1-PIGU xenografts (n ¼ 5 per group). As subcutaneous tumors reached the size of 5 to 10 mm, thyroidectomy was performed to eliminate the physiological iodine uptake. Subsequently, mice were treated with rTSH (0.1 mU/kg), followed by a second dose of rTSH and I 125 (300 mCi administered i.p.) 12 hours later. Planar scintigraphy was ARTICLE performed 36 hours later, and tumors were harvested for analysis. In vivo, K1-PIGU cells demonstrated stable PIGU expression and intense membranous NIS expression compared with K1 control tumors (3366 vs 362 positive cells per HPF, P < .001, Welch's t test) ( Figure 3A ). Scintigraphy image analysis revealed statistically significantly increased iodine uptake in K1-PIGU tumors compared with K1 controls (P ¼ .01, Welch's t test) ( Figure 3B ). Ex vivo radioactive emission revealed an approximately statistically significant higher count per million in K1-PIGU xenografts compared with K1 controls (128 945 6 28 556 vs 7963 6 192 counts per million, P < .001) ( Figure 3C ). Finally, we found a striking increase in DNA double-strand breaks, as reflected by cH2AXsignal in I 125 -treated animals harboring K1-PIGU tumors, compared with those with K1-induced tumors ( Figure 3D ). Taken together, these findings suggest that PIGU modulates NIS expression and the induction of DNA double-strand breaks in vivo.
Mitogen-Activated Protein Kinase Regulation of PIGU Levels
Recent clinical data suggest that selumetinib, a MEK inhibitor, promotes a clinically significant increase in RAI uptake in a subgroup of patients with thyroid cancer that is refractory to radioiodine therapy. Hence, we aimed to assess the role of MEK in post-translational regulation of iodine uptake. Treating primary PTC cells derived from human samples (n ¼ 4, patients 1-4) (see Supplementary Table 1 , available online) and K1 cells with a selective MEK inhibitor, U0126 (10 mM) resulted in a greater than fivefold increase in PIGU mRNA levels compared with vehicletreated cells (P < .01, Welch's t test) ( Figure 4A ). Similarly, MEK inhibition and a decreased phosphorylation of ERK induced a consistent increase in PIGU protein expression ( Figure 4B ). Immunoblotting for NIS revealed that MEK inhibition resulted in increased NIS protein levels ( Figure 4C ). for two hours, followed by 96 hours' incubation and colony formation, to determine the IC 50 . Radioiodine sensitivity in K1-PIGU cells achieved with an IC 50 value of 14.8 mCi compared with 266.2 mCi for K1 cells. All treatments were performed in triplicate, and each experiment was repeated at least three times. P values were calculated using the two-sided Welch's t test; all experiments were repeated at least three times. NIS ¼ sodium iodide symporter; RAI ¼ radioactive iodine.
The MAPK pathway is one of the most frequently dysregulated signal transduction pathways in thyroid cancer. We aimed to assess the involvement of the MAPK pathway, along with other putative pathways involved in thyroid carcinogenesis, with PIGU expression. To this end, we treated K1 cells with the MEK inhibitors PD302 (100 nmol/L) and U1206 (10 mM), or vehicle. For comparison, we tested the STAT3 inhibitor WP1660 (10 mM) and the PI3K inhibitor wortmannin (4 mM). Immunoblotting analysis revealed increased PIGU levels after MEK inhibition, but not after inhibition of the STAT3 or PI3K pathway ( Figure 4D ). Taken together, these findings suggest that the previously described effect of the MAPK pathway inhibitors on RAI uptake may be induced by upregulation of PIGU expression and GPIT activity.
PIGU Expression as a Predictor of Response to RAI in Patients With Recurrent PTC
Finally, we sought to assess the expression of PIGU in 18 patients with recurrent PTC who were treated with RAI. Patient demographic and clinical data are presented in Table 1 . Patients underwent total thyroidectomy followed by RAI treatment for their primary tumor. Upon recurrence, all patients underwent a second RAI treatment without surgery (n ¼ 18).
We compared the PIGU expression status in radioiodineavid and radioiodine-refractory tumors based on I 131 scans at recurrence. Figure 4E shows a lesion that was not radioiodine avid on diagnostic radioiodine scanning (left) and a lesion that was radioiodine avid (right). Positive I 131 uptake was present in 66.6% of patients with PIGU-positive tumors compared with only 11.1% of patients with PIGU-negative tumors (P ¼ .04, chisquare test). Moderate to strong NIS expression was found in seven of nine PIGU-positive patients compared with weak to no staining in eight of nine of the PIGU-negative group (P ¼ .01, chisquare test). Next, we assessed the decrease in thyroglobulin levels after RAI treatment according to PIGU expression in the primary tumor. Within 12 months after treatment, thyroglobulin levels decreased by a mean 75.2% in patients who had PIGU-positive tumors, compared with a mean 37.4% in those with PIGUnegative tumors (P ¼ .02, Wilcoxon signed-rank test, n ¼ 18) ( Figure 4F ). Overall seven of eight (87.5%) of the patients who were PIGU positive had a 50% or greater reduction in thyroglobulin levels compared with three of nine (33.3%) of the 
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PIGU-negative group. To study the role of PIGU in the response to RAI treatment, we performed a multivariable analysis including PIGU expression status using logistic regression. In this analysis, sex, pathology, nodal status, first I 131 dose, and PIGU were statistically significantly associated with thyroglobulin response at recurrence (PIGU hazard ratio [HR] ¼ 8.06, 95% confidence interval [CI] ¼ 3.72 to 12.3, P ¼ .001) ( Table 2) .
Discussion
Efforts to understand the origin of RAI resistance in differentiated thyroid cancer often invoke autonomous cell dedifferentiation as a primary determinant of response to therapy (26) . Studies of iodine metabolism in thyroid cancer suggested that iodine uptake dysregulation occurs regardless of genetic alterations in NIS gene expression (4, 5) . We showed here that NIS dysregulation in DTC depends on the functionality of the GPIT complex. Our findings of downregulation of PIGU in DTC, and the rescue of NIS by overexpression of PIGU, show a novel mechanism for the loss of RAI sensitivity in thyroid cancer. We also found that MEK inhibition, which was shown to restore the sensitivity of DTC to RAI (27) , upregulates PIGU and NIS expression in these cells. Finally, we found in a cohort of patients with recurrent PTC that PIGU level could predict I 131 uptake and chemical response to RAI. Our result and the finding that PIGU influences NIS glycosylation suggest that PIGU may carry auxiliary functions in the process of GPI lipid anchor attachment, either via direct interaction with NIS or indirectly, by influencing protein transport, positioning, retention, and activity of NIS within the plasmalemma domain (28) (29) (30) (31) .
Previous studies using various approaches to promote radioiodine uptake in refractory metastatic thyroid cancers have shown only marginal clinical benefit (32, 33) . Several mechanisms responsible for NIS downregulation involve RET, RAS, and BRAF mutations, which are common in PTCs (34) (35) (36) (37) . Recent data also show that treatment with the MEK inhibitor PD0325901 had a robust effect on restoration of the symporter in BRAFV600E-induced thyroid tumors (5) .
Our study provides evidence that post-translational regulation by the GPIT complex may play a key role in promoting RAI resistance during PTC progression. Post-translational downregulation of NIS in DTC can explain previous reports of an increase in NIS expression with no change in the symporter's mRNA levels (5, 6, 9) . These findings permit the recognition of a selective and specific "bottleneck" during the evolution of RAIresistant tumors. RAI is a key therapeutic modality, and loss of NIS expression is one of the most important hallmarks of thyroid cancer, leading to iodide-refractory metastatic disease and worse patient outcomes (38) . In the present study, we found that PIGU expression can predict the effect of RAI in recurrent DTC. Preventing unnecessary treatment in this population is of paramount importance, not only to avoid related morbidity and to reduce costs, but also to enable earlier treatment with small molecule inhibitors, which are indicated for these patients (2, 39, 40) . Our study has some limitations. First, it is not known to what extent our principal finding can be generalized to all cases of DTC that are resistant RAI. Furthermore, in this work, we only showed the role of PIGU in NIS glycosylation and membranous transport, whereas the exact mechanism by which PIGU modify NIS activity remains unclear. Finally, further studies are required to elucidate the mechanism by which MEK regulates PIGU expression.
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These results provide a proof of concept that posttranslational regulation has a pivotal role in iodine uptake and retention in thyroid tumors. Our data help fill the knowledge gap regarding the mechanism of action of small-molecule kinase inhibitors in enhancing iodine uptake (41) . Future profiling of patients according to GPIT complex function and NIS membrane expression is required to identify patients who can benefit from such treatment. 
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